Amarin shares fall on FDA review of Vascepa combination therapy

(Reuters) - Shares of Amarin Corporation Plc fell 20 percent on Friday on concerns the U.S. Food and Drug Administration will reject its application to market Vascepa, a drug that lowers blood fat levels, to a broader patient population. Staff reviewers for the FDA posted their assessment of Amarin's application on the agency's website on Friday, and some analysts said the review appeared more cautious than they had expected. Vascepa is currently approved as a stand-alone treatment to lower high levels of triglycerides, or blood fats, which can raise the risk of heart disease. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/amarin-shares-fall-fda-review-vascepa-combination-therapy-212805980--finance.html